Guillermo Bentabol Ramos

Mr. Guillermo Bentabol Ramos

Hospital Regional Universitario de Málaga, Málaga, Andalusia, Spain

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
GRGuillermo Bentabol Ramos
Guillermo Bentabol Ramos
RGRocío Sáenz de Santa María García
Rocío Sáenz de Santa María García
MVMonica Vidal-Diaz
Monica Vidal-Diaz
Ibon Eguíluz-GraciaIbon Eguíluz-Gracia
Ibon Eguíluz-Gracia
ATAlmudena Testera-Montes
Almudena Testera-Montes
Asthma is a heterogeneous disease in terms of both phenotype and response to therapy. Therefore, there is a great need for clinically applicable tools allowing for improved patient classification, and selection for specific management approaches. Some interventions are highly helpful in selected patients (e.g., allergen immunotherapy or aspirin desensitization), but they are costly and/or difficult to implement. Currently available biomarkers measurable in peripheral blood or exhaled air display many limitations for asthma phenotyping and cannot identify properly the specific triggers of the disease (e.g., aeroallergens or NSAID). The united airway concept illustrates the relevant epidemiological and pathophysiological links between the upper and lower airways. This concept has been largely applied to patient management and treatment, but its diagnostic implications have been less often explored. Of note, a recent document by the European Academy of Allergy and Clinical Immunology proposes the use of nasal allergen challenge to confirm the diagnosis of allergic asthma. Similarly, the nasal challenge with lysine acetylsalicylate (L-ASA) can be used to identify aspirin-sensitive asthma patients. In this review, we will summarize the main features of allergic asthma and aspirin-exacerbated respiratory disease and will discuss the methodology of nasal allergen and L-ASA challenges with a focus on their capacity to phenotype the inflammatory disease affecting both the upper and lower airways.

14 September 2024 in European Respiratory Journal
Verified
Conference Paper
Closed access
GRGuillermo Bentabol Ramos
Guillermo Bentabol Ramos
DSDulce Sánchez-Torralvo
Dulce Sánchez-Torralvo
IEIbón Eguíluz-Gracia
Ibón Eguíluz-Gracia
NPNatalia Pérez-Sánchez
Natalia Pérez-Sánchez
MFMarta Ferrer
Marta Ferrer
ATAlmudena Testera-Montes
Almudena Testera-Montes
Background: Some patients with severe asthma (SA) remain uncontrolled despite maximal inhaled therapy. Respiratory comorbidities in addition to several systemic diseases might influence the need of biologicals in subjects with T2 SA. In this work, we investigate the impact of respiratory and extra-respiratory diseases in the prescription of biologicals for SA. Method: Patients with SA from the Spanish centers of the BIOBADALER consortium were invited to participate. Their clinical and analytical data were obtained from electronic health records and entered in a RedCap© database. Data was collected in an ambispective manner. Results: 358 patients with SA provided written informed consent. 231/358 individuals (64.5%) were on biologicals. The predictors of the need for biologicals were smoking habit (p=0.001), NSAID-exacerbated respiratory disease (NERD)(p=0.01), chronic rhinosinusitis (CRS)(p=0.001), chronic rhinosinusitis with nasal polyps (CRSwNP)(p<0.001), gastroesphageal reflux disease (GERD)(p=0.028), Obstructive sleep apnea/hypopnea syndrome (OSAHS)(p=0.024), depression/anxiety (p=0.002) and cardiovascular disease (p=0.005). Conversely, atopy, food allergy, atopic dermatitis, obesity and asthma-COPD overlap syndrome (ACOS) did not influence the prescription of biologicals. Conclusion: Respiratory comorbidities related to T2 inflammation (CRSwNP and NERD) increase the need of biologicals in SA patients. Nevertheless, other respiratory (smoking, OSAHS) and extra-respiratory (GERD, depression/anxiety, and cardiovascular disease) conditions not related to T2 inflammation are also more frequent in SA subjects on biologicals as compared to patients off biologicals.